Evaluation of Interleukins and Biochemical Markers Levels Among COVID-19 Iraqi Patients

• Дата: 2025
• Автори: Al-Jubury, Kutaiba Sattar, Abdulmunem, Osama, Najm, Hamsa Faisal, Alshareef, Duraid Kassim Jassim, Аль-Джубурі, Кутаїба Саттар, Абдулмунем, Осама, Наджм, Хамса Файсал, Альшаріф, Дураїд Касім Джасім
• Формат: Стаття
• Мова: English
• Опубліковано: PH "Akademperiodyka" of the NAS of Ukraine 2025
• Онлайн доступ: https://ojs.microbiolj.org.ua/index.php/mj/article/view/334
• Назва журналу: Microbiological Journal

The World Health Organization (WHO) classified the novel coronavirus Corona (SARS-CoV-2 virus (pandemic that occurred on March 11, 2020, which is the eleventh pandemic to hit the world in the last hundred years. Consequently, it has become necessary to identify the potential biomarkers that can quickly and accurately identify severe cases of the disease caused by this novel virus. From January 20, 2022, to June 30, 2022, clinical samples from 150 patients (75 males and 75 females) in Baghdad Medical City were collected and statistically analyzed in this study for Interleukins and biochemical markers levels. The samples were subjected to a Real-Time Reverse Transcription Polymerase Chain Reaction Assay (RT-PCR) to establish the disease. When the patient and recovery groups were compared, the differences in the interleukins and biochemical levels were statistically significant (p<0.001). After 3 weeks of treatment, the interleukins and biochemical levels in the recovery phase patient group were significantly lower than in the acute phase group (p<0.001). Hence, the IL2, IL4, and IL-6 levels are considerably higher in COVID-19 patients,” which are linked to less favorable clinical outcomes. Conclusions. Conclusively, high-quality intervention studies are urgently needed in this area, especially on the inhibition of the IL-2, IL-4, and IL-6 levels, which could be a creative manner of treating patients with COVID-19 who have dysregulated host responses.